Manoharan, Arumugam (2013) Dasatinib-Induced Hepatic Dysfunction. International Journal of Clinical Medicine, 04 (01). pp. 8-9. ISSN 2158-284X
Text
IJCM_2013011813432888.pdf - Published Version
Download (67kB)
IJCM_2013011813432888.pdf - Published Version
Download (67kB)
Official URL: https://doi.org/10.4236/ijcm.2013.41003
Abstract
A 53-year-old man with chronic myeloid leukaemia developed significant hepatic dysfunction when treatment was changed from imatinib (because of drug-induced rash) to dasatinib. Liver function tests returned to normal 77 days after cessation of therapy and have remained normal despite recommencement of dasatinib. Although the pathogenesis for the significant hepatic dysfunction is unclear, this case illustrates the reversibility of this event with dose interruption and that dasatinib can be safely recommenced for ongoing treatment.
Item Type: | Article |
---|---|
Subjects: | GO for STM > Medical Science |
Depositing User: | Unnamed user with email support@goforstm.com |
Date Deposited: | 07 Jan 2023 10:10 |
Last Modified: | 25 Aug 2023 05:59 |
URI: | http://archive.article4submit.com/id/eprint/17 |